CDKN1A Gene Expression in Two Multiple Myeloma Cell Lines With Different P53 Functionality

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Multiple myeloma is a complex plasma cell cancer.
• Histone deacetylase (HDAC) inhibitors are promising cancer treatments.
• The exact mechanisms of HDAC inhibitors are not fully understood.

Purpose of the Study:

• To investigate the effects of HDAC inhibitors on multiple myeloma cells.
• To analyze cell-cycle regulation and apoptosis induced by SAHA and SBHA.
• To explore the role of TP53 status in the response to HDAC inhibitors.

Main Methods:

• Utilized multiple myeloma cell lines (RPMI8226 and U266) with different TP53 statuses.
• Administered two HDAC inhibitors: suberohydroxamic acid (SAHA) and suberoylanilide hydroxamic acid (SBHA).
• Performed gene-expression analysis to assess cellular responses.

Main Results:

• SAHA treatment upregulated CDKN1A/p21 in TP53-deleted U266 cells, suggesting P53-independent activation.
• Both SAHA and SBHA significantly increased CDKN1A gene expression in TP53-mutated RPMI8226 cells.
• HDAC inhibitors demonstrate differential effects based on TP53 genetic status.

Conclusions:

• SAHA exhibits potential as a pro-apoptotic and anticancer agent for multiple myeloma.
• SAHA may be effective across diverse multiple myeloma patient populations.
• Further research into HDAC inhibitors' mechanisms is warranted.